[
  {
    "trial": "T017",
    "source": "abstract",
    "arms": {
      "Group D (dexamethasone)": {"randomized": "99", "analysed": null},
      "Group KD (ketamine + dexamethasone)": {"randomized": "99", "analysed": null}
    },
    "depression": [],
    "pain": [],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": null,
    "registration": null,
    "note": "Abstract only. Group K (ketamine alone, n = 99) has role 'other' in the design and is left out. 'n = 99' per group is the allocation of the 297 patients 'randomly allocated ... into three groups'; no analysed numbers. PHQ-9 (days 1 and 3 against preoperative), VAS at 24 h and PCA consumption are given only as significance statements (P < 0.01; P < 0.05), with no values. No adverse events, dates or registration in the abstract."
  },
  {
    "trial": "T023",
    "source": "abstract",
    "arms": {
      "Group C": {"randomized": null, "analysed": "49"},
      "Group K": {"randomized": null, "analysed": "48"}
    },
    "depression": [],
    "pain": [
      {"measure": "QoR-40 pain subsection score", "day": 1, "form": "mean_sd", "location": "abstract, Results",
       "values": {"Group C": {"mean": "29.8", "sd": "3.8", "n": "49"}, "Group K": {"mean": "31.7", "sd": "2.1", "n": "48"}}}
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": null,
    "registration": null,
    "note": "Abstract only. 100 randomised 1:1; per-arm numbers not printed. 'analysed' is the number with QoR-40 on POD1 (49 group C, 48 group K), the only per-arm count given. HADS (day 2, 3 months), NRS (4, 24, 48 h) and chronic pain at 3 months have no values, only 'no difference (p value for each >.15)'. The pain entry is not a design measure: it is the post hoc QoR-40 pain subsection on POD1 (a recovery score, higher means better). Its arm order is ambiguous: the abstract prints 'pain scores were significantly higher in group K than in group C (29.8 ± 3.8 vs. 31.7 ± 2.1, 95% CI -1.81 (-3.00, -0.62))'. Entered as C 29.8 and K 31.7, because K is said to be higher and the difference is negative, as in the global-score comparison written 'group C and group K (169.8 ± 10.7 vs. 172.7 ± 7.5, 95% CI -1.35 ...)'. Its n is the POD1 QoR-40 n."
  },
  {
    "trial": "T028",
    "source": "abstract",
    "arms": {
      "Control group (normal saline)": {"randomized": null, "analysed": null},
      "Racemic ketamine group": {"randomized": null, "analysed": null},
      "S-ketamine group": {"randomized": null, "analysed": null}
    },
    "depression": [],
    "pain": [],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2017-06", "end": "2018-06"},
    "registration": null,
    "note": "Abstract only. 303 patients randomly divided into three groups; per-arm numbers not printed. HAMD-17 (3 days, 1 week, 1 month, 3 months) and VAS (1 and 3 days) are given only as significance statements, with no values; complications only as 'no significant difference'. Enrollment period is from the abstract's Methods ('from June 2017 to June 2018')."
  },
  {
    "trial": "T044",
    "source": "fulltext",
    "arms": {
      "Group E": {"randomized": "60", "analysed": "58"},
      "Group C": {"randomized": "60", "analysed": "59"}
    },
    "depression": [
      {"measure": "EPDS (with diagnostic criteria)", "day": 7, "form": "count", "definition": "PPD diagnosed from EPDS score and diagnostic criteria for mental disorders (refs 15, 16); no cut-off stated", "location": "Table 3",
       "values": {"Group E": {"events": "2", "n": "58"}, "Group C": {"events": "9", "n": "59"}}},
      {"measure": "EPDS (with diagnostic criteria)", "day": 42, "form": "count", "definition": "PPD diagnosed from EPDS score and diagnostic criteria for mental disorders (refs 15, 16); no cut-off stated", "location": "Table 3",
       "values": {"Group E": {"events": "3", "n": "58"}, "Group C": {"events": "11", "n": "59"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 3",
       "values": {"Group E": {"nightmare": "2"}, "Group C": {"nightmare": "3"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2022-06-01", "end": "2023-02-28"},
    "registration": {"number": "ChiCTR2200060387", "date": "2022-05-30"},
    "note": "Randomized '60' per arm is from Methods ('A total of 120 samples were designed in this study, for 60 in each group'); Results: 120 enrolled, 2 excluded in Group E and 1 in Group C, leaving 58 and 59 analysed. Vaginal delivery with epidural labour analgesia; esketamine given after fetal disengagement, so day 0 is delivery. Text percentages for PPD (3.4% vs 15.3%, 5.2% vs 18.6%) match Table 3. Side effects were recorded for 48 h after delivery (entered as postoperative); nausea/vomiting (2 vs 1) and drowsiness (1 vs 1) are not coded categories. Enrollment dates are from Methods ('from 6/1/2022 to 2/28/2023', month/day/year). The paper calls the registry number a 'CTRI registration number', but it is ChiCTR, registered 5/30/2022 at the Chinese Clinical Trial Registry."
  },
  {
    "trial": "T060",
    "source": "fulltext",
    "arms": {
      "Morning operation with esketamine": {"randomized": "108", "analysed": "107"},
      "Morning operation with saline": {"randomized": "108", "analysed": "105"},
      "Afternoon operation with esketamine": {"randomized": "108", "analysed": "106"},
      "Afternoon operation with saline": {"randomized": "108", "analysed": "108"}
    },
    "depression": [
      {"measure": "Hospital Anxiety and Depression Scale (HAD)", "day": -1, "form": "median_iqr", "location": "Table 3",
       "values": {
         "Morning operation with esketamine": {"median": "4", "q1": "3", "q3": "6", "n": "108"},
         "Morning operation with saline": {"median": "5", "q1": "3", "q3": "7", "n": "108"},
         "Afternoon operation with esketamine": {"median": "4", "q1": "2", "q3": "6", "n": "108"},
         "Afternoon operation with saline": {"median": "4", "q1": "3", "q3": "6", "n": "108"}}},
      {"measure": "Hospital Anxiety and Depression Scale (HAD)", "day": 1, "form": "median_iqr", "location": "Table 3",
       "values": {
         "Morning operation with esketamine": {"median": "8", "q1": "7", "q3": "10", "n": "107"},
         "Morning operation with saline": {"median": "8", "q1": "7", "q3": "10", "n": "105"},
         "Afternoon operation with esketamine": {"median": "8", "q1": "6", "q3": "10", "n": "106"},
         "Afternoon operation with saline": {"median": "8", "q1": "6", "q3": "10", "n": "108"}}},
      {"measure": "Hospital Anxiety and Depression Scale (HAD)", "day": 3, "form": "median_iqr", "location": "Table 3",
       "values": {
         "Morning operation with esketamine": {"median": "8", "q1": "6", "q3": "10", "n": "107"},
         "Morning operation with saline": {"median": "8", "q1": "6", "q3": "9", "n": "105"},
         "Afternoon operation with esketamine": {"median": "7", "q1": "6", "q3": "9", "n": "106"},
         "Afternoon operation with saline": {"median": "8", "q1": "6", "q3": "10", "n": "108"}}},
      {"measure": "Hospital Anxiety and Depression Scale (HAD)", "day": 7, "form": "median_iqr", "location": "Table 3",
       "values": {
         "Morning operation with esketamine": {"median": "7", "q1": "6", "q3": "9", "n": "107"},
         "Morning operation with saline": {"median": "7", "q1": "5", "q3": "9", "n": "105"},
         "Afternoon operation with esketamine": {"median": "7", "q1": "5", "q3": "9", "n": "106"},
         "Afternoon operation with saline": {"median": "7", "q1": "5", "q3": "9", "n": "108"}}}
    ],
    "pain": [
      {"measure": "postoperative NRS", "day": 1, "form": "median_iqr", "location": "Table 6",
       "values": {
         "Morning operation with esketamine": {"median": "2", "q1": "1", "q3": "3", "n": "107"},
         "Morning operation with saline": {"median": "2", "q1": "1", "q3": "3", "n": "105"},
         "Afternoon operation with esketamine": {"median": "2", "q1": "1", "q3": "3", "n": "106"},
         "Afternoon operation with saline": {"median": "2", "q1": "1", "q3": "3", "n": "108"}}},
      {"measure": "postoperative NRS", "day": 2, "form": "median_iqr", "location": "Table 6",
       "values": {
         "Morning operation with esketamine": {"median": "2", "q1": "1", "q3": "3", "n": "107"},
         "Morning operation with saline": {"median": "2", "q1": "1", "q3": "3", "n": "105"},
         "Afternoon operation with esketamine": {"median": "2", "q1": "1", "q3": "3", "n": "106"},
         "Afternoon operation with saline": {"median": "3", "q1": "1", "q3": "4", "n": "108"}}}
    ],
    "adverse_events": [
      {"window": "emergence", "location": "Table 9, PACU",
       "values": {
         "Morning operation with esketamine": {"agitation": "19", "dizziness": "33"},
         "Morning operation with saline": {"agitation": "31", "dizziness": "24"},
         "Afternoon operation with esketamine": {"agitation": "18", "dizziness": "21"},
         "Afternoon operation with saline": {"agitation": "28", "dizziness": "18"}}},
      {"window": "postoperative", "location": "Table 9, Postoperation",
       "values": {
         "Morning operation with esketamine": {"dizziness": "34"},
         "Morning operation with saline": {"dizziness": "46"},
         "Afternoon operation with esketamine": {"dizziness": "42"},
         "Afternoon operation with saline": {"dizziness": "40"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2022-01-04", "end": "2023-03-07"},
    "registration": null,
    "note": "2x2 factorial; the tables' AES, ANS, MES and MNS are the afternoon/morning esketamine/saline arms. Randomized '108' per arm is the n of Table 3's preoperation row (432 randomized 1:1:1:1; the flow chart is not in the text). Analysed 106/108/107/105 (AES/ANS/MES/MNS; 426 analysed, the n in Tables 1, 3, 6, 8 and 9). HAD is reported as one total score (median, IQR), not by subscale. HAD and NRS 'postoperative day' visits were in the morning; the first came at least 20 h after morning and 14 h after afternoon operations, so the afternoon arms' day-1 NRS may fall under 18 h. GEE estimates (esketamine vs saline: B = -0.054 for HAD, -0.010 for NRS) are not entered. PACU events are entered as emergence (EA = emergence agitation, and PACU dizziness); 'Postoperation' dizziness as postoperative. Postoperative delirium (3D-CAM, the primary outcome) is not entered as an adverse event. Enrollment dates are from Methods. No registration number in the text."
  },
  {
    "trial": "T070",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": null, "analysed": "40"},
      "Control group": {"randomized": null, "analysed": "40"}
    },
    "depression": [
      {"measure": "PHQ-9", "day": -1, "form": "count", "definition": "PHQ-9 score ≥ 5", "location": "Table 1",
       "values": {"Esketamine group": {"events": "2", "n": "40"}, "Control group": {"events": "0", "n": "40"}}},
      {"measure": "PHQ-9", "day": 1, "form": "count", "definition": "PHQ-9 score ≥ 5", "location": "Table 2",
       "values": {"Esketamine group": {"events": "1", "n": "40"}, "Control group": {"events": "3", "n": "40"}}},
      {"measure": "PHQ-9", "day": 2, "form": "count", "definition": "PHQ-9 score ≥ 5", "location": "Table 2",
       "values": {"Esketamine group": {"events": "1", "n": "40"}, "Control group": {"events": "6", "n": "40"}}}
    ],
    "pain": [
      {"measure": "VAS pain score", "day": 1, "form": "mean_sd", "location": "Table 2, VAS at T2 (postoperative day 1 morning)",
       "values": {"Esketamine group": {"mean": "2.55", "sd": "1.02", "n": "40"}, "Control group": {"mean": "2.75", "sd": "0.75", "n": "40"}}},
      {"measure": "VAS pain score", "day": 1, "form": "mean_sd", "location": "Table 2, VAS at T3 (postoperative day 1 afternoon)",
       "values": {"Esketamine group": {"mean": "2.58", "sd": "0.82", "n": "40"}, "Control group": {"mean": "2.89", "sd": "0.65", "n": "40"}}},
      {"measure": "VAS pain score", "day": 2, "form": "mean_sd", "location": "Table 2, VAS at T4 (postoperative day 2 morning)",
       "values": {"Esketamine group": {"mean": "2.66", "sd": "0.68", "n": "40"}, "Control group": {"mean": "3.14", "sd": "0.70", "n": "40"}}},
      {"measure": "VAS pain score", "day": 2, "form": "mean_sd", "location": "Table 2, VAS at T5 (postoperative day 2 afternoon)",
       "values": {"Esketamine group": {"mean": "2.58", "sd": "0.83", "n": "40"}, "Control group": {"mean": "3.16", "sd": "0.67", "n": "40"}}}
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2022-07-07", "end": "2023-02-20"},
    "registration": null,
    "note": "Per-arm randomized numbers are not printed (flow chart not in the text); analysed 40 per arm ('The final analysis included a total of 80 patients, with 40 patients in each group'), intention to treat. PHQ-9 is reported only as counts with PHQ-9 ≥ 5; the baseline row is Table 1. VAS was measured twice on each postoperative day (T2 8:00-10:00 a.m. and T3 3:00-5:00 p.m. on day 1, T4 and T5 on day 2); all four are entered, two per day, told apart by location, since hours after surgery are not given. Not entered: VAS at T1 (5 min after extubation); 'VAS >3 within 48 h' 11 (27.5 %) vs 17 (42.5 %), cumulative over 48 h rather than at a time; flurbiprofen and paracetamol use (non-opioid rescue). The study drug ran in the postoperative analgesia pump for 24 h. The only adverse event reported is PONV (10 vs 10), not a coded category. Enrollment dates are from Methods. The paper says it was registered on ClinicalTrials.gov but gives no number or date."
  },
  {
    "trial": "T094",
    "source": "fulltext",
    "arms": {
      "Control group": {"randomized": "100", "analysed": "100"},
      "Esketamine group": {"randomized": "100", "analysed": "100"}
    },
    "depression": [
      {"measure": "HADS-D", "day": -1, "form": "mean_sd", "location": "Table 1",
       "values": {"Control group": {"mean": "8.2", "sd": "2.4", "n": "100"}, "Esketamine group": {"mean": "8.1", "sd": "2.5", "n": "100"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "overall", "location": "Table 4",
       "values": {"Control group": {"dizziness": "9", "dissociation": "3"}, "Esketamine group": {"dizziness": "6", "dissociation": "15"}}}
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": {"number": "ChiCTR2400087795", "date": null},
    "note": "Allocation 'control group (n = 100) and esketamine group (n = 100)'; every table uses n = 100 per arm. Baseline HADS-D (Table 1) was collected one day before surgery. HADS-D on postoperative days 1 and 3, VAS at 24 and 48 h, opioid consumption and the rescue analgesia rate appear only in Fig. 2 with no printed values, so none is entered. The adverse events in Table 4 have no stated time window, entered as overall; 'Dizziness or Lightheadedness' is entered as dizziness and 'Dissociative Symptoms' as dissociation; nausea or vomiting (15 vs 10), headache (10 vs 12) and sedation (7 vs 5) are not coded categories (control vs esketamine). No enrollment dates; registration number without a date."
  },
  {
    "trial": "T107",
    "source": "fulltext",
    "arms": {
      "Bolus group": {"randomized": "168", "analysed": "153"},
      "Infusion group": {"randomized": "168", "analysed": "156"},
      "Control group": {"randomized": "167", "analysed": "150"}
    },
    "depression": [
      {"measure": "EPDS", "day": -1, "form": "median_iqr", "location": "Table 1",
       "values": {"Bolus group": {"median": "5", "q1": "2", "q3": "7", "n": "153"}, "Infusion group": {"median": "5", "q1": "2", "q3": "7", "n": "156"}, "Control group": {"median": "4.5", "q1": "1", "q3": "6", "n": "150"}}},
      {"measure": "EPDS", "day": 7, "form": "count", "definition": "positive PPD screen, EPDS 'more than 10' (Methods); see note", "location": "Table 2",
       "values": {"Bolus group": {"events": "16", "n": "147"}, "Infusion group": {"events": "17", "n": "148"}, "Control group": {"events": "22", "n": "145"}}},
      {"measure": "EPDS", "day": 28, "form": "count", "definition": "positive PPD screen, EPDS 'more than 10' (Methods); see note", "location": "Table 2",
       "values": {"Bolus group": {"events": "18", "n": "150"}, "Infusion group": {"events": "15", "n": "147"}, "Control group": {"events": "23", "n": "145"}}},
      {"measure": "EPDS", "day": 42, "form": "count", "definition": "positive PPD screen, EPDS 'more than 10' (Methods); see note", "location": "Table 2",
       "values": {"Bolus group": {"events": "14", "n": "153"}, "Infusion group": {"events": "18", "n": "156"}, "Control group": {"events": "29", "n": "150"}}},
      {"measure": "EPDS", "day": 7, "form": "median_iqr", "location": "Table 2",
       "values": {"Bolus group": {"median": "3", "q1": "0", "q3": "6", "n": "147"}, "Infusion group": {"median": "4", "q1": "1", "q3": "6", "n": "148"}, "Control group": {"median": "3", "q1": "0", "q3": "6", "n": "145"}}},
      {"measure": "EPDS", "day": 28, "form": "median_iqr", "location": "Table 2",
       "values": {"Bolus group": {"median": "2", "q1": "0", "q3": "6", "n": "150"}, "Infusion group": {"median": "2", "q1": "0", "q3": "7", "n": "147"}, "Control group": {"median": "2", "q1": "0", "q3": "7", "n": "145"}}},
      {"measure": "EPDS", "day": 42, "form": "median_iqr", "location": "Table 2",
       "values": {"Bolus group": {"median": "2", "q1": "0", "q3": "5", "n": "153"}, "Infusion group": {"median": "2", "q1": "0", "q3": "5.75", "n": "156"}, "Control group": {"median": "3", "q1": "0", "q3": "7", "n": "150"}}},
      {"measure": "EPDS", "day": 7, "form": "count", "definition": "EPDS ≥ 11 (sensitivity analysis)", "location": "Table 2",
       "values": {"Bolus group": {"events": "10", "n": "147"}, "Infusion group": {"events": "13", "n": "148"}, "Control group": {"events": "16", "n": "145"}}},
      {"measure": "EPDS", "day": 28, "form": "count", "definition": "EPDS ≥ 11 (sensitivity analysis)", "location": "Table 2",
       "values": {"Bolus group": {"events": "15", "n": "150"}, "Infusion group": {"events": "11", "n": "147"}, "Control group": {"events": "19", "n": "145"}}},
      {"measure": "EPDS", "day": 42, "form": "count", "definition": "EPDS ≥ 11 (sensitivity analysis)", "location": "Table 2",
       "values": {"Bolus group": {"events": "8", "n": "153"}, "Infusion group": {"events": "12", "n": "156"}, "Control group": {"events": "25", "n": "150"}}},
      {"measure": "EPDS", "day": 7, "form": "count", "definition": "EPDS ≥ 12 (sensitivity analysis)", "location": "Table 2",
       "values": {"Bolus group": {"events": "8", "n": "147"}, "Infusion group": {"events": "12", "n": "148"}, "Control group": {"events": "6", "n": "145"}}},
      {"measure": "EPDS", "day": 28, "form": "count", "definition": "EPDS ≥ 12 (sensitivity analysis)", "location": "Table 2",
       "values": {"Bolus group": {"events": "12", "n": "150"}, "Infusion group": {"events": "9", "n": "147"}, "Control group": {"events": "12", "n": "145"}}},
      {"measure": "EPDS", "day": 42, "form": "count", "definition": "EPDS ≥ 12 (sensitivity analysis)", "location": "Table 2",
       "values": {"Bolus group": {"events": "7", "n": "153"}, "Infusion group": {"events": "9", "n": "156"}, "Control group": {"events": "18", "n": "150"}}}
    ],
    "pain": [
      {"measure": "NRS at rest", "day": 1, "form": "median_iqr", "location": "Results, Pain Control paragraph",
       "values": {"Bolus group": {"median": "3", "q1": "2", "q3": "3", "n": null}, "Infusion group": {"median": "3", "q1": "2", "q3": "3", "n": null}, "Control group": {"median": "3", "q1": "2", "q3": "3", "n": null}}},
      {"measure": "NRS at rest", "day": 2, "form": "median_iqr", "location": "Results, Pain Control paragraph",
       "values": {"Bolus group": {"median": "1", "q1": "0", "q3": "2", "n": null}, "Infusion group": {"median": "1", "q1": "0", "q3": "2", "n": null}, "Control group": {"median": "1", "q1": "0", "q3": "2", "n": null}}},
      {"measure": "NRS with movement (coughing or walking)", "day": 1, "form": "median_iqr", "location": "Results, Pain Control paragraph",
       "values": {"Bolus group": {"median": "4", "q1": "4", "q3": "5", "n": null}, "Infusion group": {"median": "4", "q1": "4", "q3": "5", "n": null}, "Control group": {"median": "4", "q1": "3", "q3": "5", "n": null}}},
      {"measure": "NRS with movement (coughing or walking)", "day": 2, "form": "median_iqr", "location": "Results, Pain Control paragraph",
       "values": {"Bolus group": {"median": "3", "q1": "3", "q3": "4", "n": null}, "Infusion group": {"median": "3", "q1": "3", "q3": "4", "n": null}, "Control group": {"median": "3", "q1": "3", "q3": "4", "n": null}}},
      {"measure": "PCIA usage (fentanyl)", "day": 2, "form": "mean_sd", "location": "Results, Pain Control, PCIA paragraph",
       "values": {"Bolus group": {"mean": "69.25", "sd": "12.04", "n": null}, "Infusion group": {"mean": "68.73", "sd": "12.31", "n": null}, "Control group": {"mean": "69.92", "sd": "12.75", "n": null}}}
    ],
    "adverse_events": [
      {"window": "intraoperative", "location": "Table 3, During surgery",
       "values": {
         "Bolus group": {"dizziness": "22", "nightmare": "6", "hallucination": "13", "any_ae": "70"},
         "Infusion group": {"dizziness": "47", "nightmare": "9", "hallucination": "5", "any_ae": "102"},
         "Control group": {"dizziness": "5", "nightmare": "0", "hallucination": "0", "any_ae": "33"}}},
      {"window": "postoperative", "location": "Table 3, Within 6 weeks postpartum",
       "values": {"Bolus group": {"any_ae": "17"}, "Infusion group": {"any_ae": "23"}, "Control group": {"any_ae": "20"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-04", "end": "2025-04"},
    "registration": {"number": "ChiCTR2400082919", "date": null},
    "note": "Per-protocol analysis (150/153/156 completed). Main PPD definition: Methods say 'EPDS scores more than 10', but the sensitivity rows at ≥ 11 and ≥ 12 differ from the main rows, and Statistical analysis calls ≥ 10 the common cut-off, so the main rows are probably EPDS ≥ 10. The EPDS medians have no n of their own; their n is the denominator of the PPD row at the same time. Baseline EPDS (Table 1) is for those analysed. ITT worst-case percentages (17.85% vs 17.26%) not entered. Pain values are from the text, which lists three values per time without naming groups; taken in the tables' order Control, Bolus, Infusion (the bolus-attempt percentages in the next paragraph fit n = 150/153/156 in that order). The Infusion group's day-1 rest value is printed '3 3 (2–3)', entered as median 3. NRS on day 3 not entered. PCIA 'total agent' consumption (unit not stated; PCIA of fentanyl 10 µg/mL, stopped within 48 h) is entered at day 2; bolus frequencies 2 (0–6) vs 2 (0–4) vs 2 (0–5) (IQR or range not said) and bolus-attempt incidence 50.66% vs 54.90% vs 55.12% are not entered (Control, Bolus, Infusion). AEs: 'Dreamscape' entered as nightmare (it could be read as dissociation). Diplopia (0/1/0) and nystagmus (0/1/0, Control/Bolus/Infusion) are separate rows, so 'visual' is left out: the number with either is not printed. 'In total' equals the sum of the rows in every group, so it may count events rather than participants. 'During surgery' events were asked about at the end of surgery under spinal anaesthesia. Enrollment period is from Methods."
  },
  {
    "trial": "T116",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "68", "analysed": "68"},
      "Normal saline group": {"randomized": "68", "analysed": "68"}
    },
    "depression": [
      {"measure": "EPDS", "day": 2, "form": "mean_sd", "location": "Table 2, Total scores",
       "values": {"Esketamine group": {"mean": "21.10", "sd": "2.02", "n": "68"}, "Normal saline group": {"mean": "23.34", "sd": "2.01", "n": "68"}}},
      {"measure": "EPDS", "day": 3, "form": "count", "definition": "PPD (definition not stated)", "location": "Results, Comparison of postpartum depression (PPD) incidence",
       "values": {"Esketamine group": {"events": "4", "n": null}, "Normal saline group": {"events": "15", "n": null}}},
      {"measure": "EPDS", "day": 7, "form": "mean_sd", "location": "Table 3, Total scores",
       "values": {"Esketamine group": {"mean": "17.86", "sd": "2.17", "n": "68"}, "Normal saline group": {"mean": "20.55", "sd": "2.21", "n": "68"}}}
    ],
    "pain": [
      {"measure": "number of compressions of the analgesic pump", "day": 1, "form": "mean_sd", "location": "Table 4, within 24 hours after the operation (times)",
       "values": {"Esketamine group": {"mean": "2.57", "sd": "0.74", "n": "68"}, "Normal saline group": {"mean": "4.15", "sd": "1.22", "n": "68"}}},
      {"measure": "number of compressions of the analgesic pump", "day": 2, "form": "mean_sd", "location": "Table 4, within 48 hours after the operation (times)",
       "values": {"Esketamine group": {"mean": "3.55", "sd": "1.24", "n": "68"}, "Normal saline group": {"mean": "4.75", "sd": "1.33", "n": "68"}}}
    ],
    "adverse_events": [
      {"window": "intraoperative", "location": "Table 6",
       "values": {
         "Esketamine group": {"dizziness": "14", "hallucination": "1", "dissociation": "1", "agitation": "1", "visual": "2"},
         "Normal saline group": {"dizziness": "11", "hallucination": "2", "dissociation": "3", "agitation": "1", "visual": "1"}}},
      {"window": "postoperative", "location": "Table 6, Postoperative rows",
       "values": {"Esketamine group": {"dizziness": "3"}, "Normal saline group": {"dizziness": "4"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-08", "end": "2025-08"},
    "registration": {"number": "ChiCTR2400088992", "date": null},
    "note": "Single-blind (mothers only). The paper's 'study group' is the Esketamine group and 'control group' the Normal saline group; Tables 2 and 3 list Control first. EPDS totals are copied as printed (23.34 vs 21.10 on day 2), high beside the PPD rates. PPD (definition not stated) on postoperative day 3: 4 (5.88%) vs 15 (22.06%), n not printed (the percentages fit 68 per arm). Days 7 and 14 give percentages only (5.08% vs 22.41%; 5.08% vs 20.69%), which imply fewer than 68 assessed although Tables 2 and 3 show n = 68; day 30 'not statistically significant' without values; none entered. VAS at rest and during movement (4, 12, 24 h) is only in Fig. 4, not entered. The pain entries are not design measures: PCIA pump presses within 24 h and 48 h (Table 4; PCIA of butorphanol, flurbiprofen and dexamethasone). AEs (Table 6): rows without 'Postoperative' are intraoperative, as the text says; 'Illusion' is entered as hallucination (the text names hallucinations), 'Restless and agitated' as agitation, nystagmus as visual; postoperative events were monitored for 24 h. Enrollment period is from Methods."
  },
  {
    "trial": "T121",
    "source": "library",
    "arms": {
      "Esketamine group": {"randomized": "87", "analysed": "85"},
      "Control group (normal saline; PCIA without esketamine)": {"randomized": "87", "analysed": "84"}
    },
    "depression": [
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": -1, "form": "median_iqr", "location": "Table 1, Preoperative EPDS Score",
       "values": {"Esketamine group": {"median": "12", "q1": "10", "q3": "13", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"median": "12", "q1": "10.8", "q3": "14", "n": "84"}}},
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": 3, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "9.0", "q1": "7.0", "q3": "11.0", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"median": "10.0", "q1": "8.8", "q3": "13.0", "n": "84"}}},
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": 3, "form": "count", "definition": "EPDS score ≥ 10", "location": "Table 2",
       "values": {"Esketamine group": {"events": "37", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"events": "53", "n": "84"}}},
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": 42, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "6.0", "q1": "3.0", "q3": "9.0", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"median": "7.0", "q1": "4.0", "q3": "11.3", "n": "84"}}},
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": 42, "form": "count", "definition": "EPDS score ≥ 10", "location": "Table 2",
       "values": {"Esketamine group": {"events": "16", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"events": "33", "n": "84"}}},
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": 3, "form": "count", "definition": "EPDS score ≥ 13 (exploratory)", "location": "Table 2",
       "values": {"Esketamine group": {"events": "11", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"events": "22", "n": "84"}}},
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": 42, "form": "count", "definition": "EPDS score ≥ 13 (exploratory)", "location": "Table 2",
       "values": {"Esketamine group": {"events": "5", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"events": "15", "n": "84"}}},
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": 3, "form": "count", "definition": "EPDS score ≥ 12 (exploratory)", "location": "Table 2",
       "values": {"Esketamine group": {"events": "13", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"events": "30", "n": "84"}}},
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": 42, "form": "count", "definition": "EPDS score ≥ 12 (exploratory)", "location": "Table 2",
       "values": {"Esketamine group": {"events": "7", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"events": "21", "n": "84"}}},
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": 3, "form": "count", "definition": "EPDS score ≥ 11 (exploratory)", "location": "Table 2",
       "values": {"Esketamine group": {"events": "22", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"events": "39", "n": "84"}}},
      {"measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)", "day": 42, "form": "count", "definition": "EPDS score ≥ 11 (exploratory)", "location": "Table 2",
       "values": {"Esketamine group": {"events": "12", "n": "85"}, "Control group (normal saline; PCIA without esketamine)": {"events": "24", "n": "84"}}}
    ],
    "pain": [
      {"measure": "NRS pain scores at rest and during coughing", "day": 1, "form": "median_iqr", "location": "Results 3.3, first paragraph (24 h)",
       "values": {"Esketamine group": {"median": "3.0", "q1": "2.0", "q3": "4.0", "n": null}, "Control group (normal saline; PCIA without esketamine)": {"median": "4.0", "q1": "3.0", "q3": "5.0", "n": null}}},
      {"measure": "Cumulative sufentanil consumption (0-12, 12-24, 0-24, 24-48, 0-48 h)", "day": 1, "form": "mean_sd", "location": "Results 3.3, second paragraph (0–24 h)",
       "values": {"Esketamine group": {"mean": "33.5", "sd": "9.7", "n": null}, "Control group (normal saline; PCIA without esketamine)": {"mean": "48.2", "sd": "11.8", "n": null}}},
      {"measure": "Cumulative sufentanil consumption (0-12, 12-24, 0-24, 24-48, 0-48 h)", "day": 2, "form": "mean_sd", "location": "Results 3.3, second paragraph (total 48-h)",
       "values": {"Esketamine group": {"mean": "59.4", "sd": "11.6", "n": null}, "Control group (normal saline; PCIA without esketamine)": {"mean": "75.5", "sd": "14.1", "n": null}}}
    ],
    "adverse_events": [
      {"window": "intraoperative", "location": "Table 3, Adverse effects during the operation",
       "values": {
         "Esketamine group": {"dizziness": "27", "hallucination": "5", "nightmare": "2"},
         "Control group (normal saline; PCIA without esketamine)": {"dizziness": "9", "hallucination": "0", "nightmare": "0"}}},
      {"window": "postoperative", "location": "Table 3, Adverse effects after surgery",
       "values": {
         "Esketamine group": {"dizziness": "9", "hallucination": "2", "nightmare": "2"},
         "Control group (normal saline; PCIA without esketamine)": {"dizziness": "2", "hallucination": "0", "nightmare": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-10-20", "end": "2024-06-16"},
    "registration": {"number": "ChiCTR2300077191", "date": null},
    "note": "Library PDF text; table columns are mangled but readable (Table 2 has a stray column of Table 1's P values). n for Table 1 and 2 entries is the tables' column N (85/84). The ≥ 11, ≥ 12 and ≥ 13 rows are Table 2's exploratory analysis. Pain: the text gives one set of values for 'NRS pain scores at rest and during coughing' at 6, 12 and 24 h without saying whether they are at rest or during coughing, so the 24-h values are entered under the source's wording; Fig. 2 (mean ± SD, no printed values) shows both; 48 h only 'comparable (P > 0.05)'. Sufentanil in µg: 0–24 h entered as day 1 and total 0–48 h as day 2; also printed, esketamine vs control: 0–12 h 17.7 ± 6.0 vs 27.6 ± 6.4, 12–24 h 15.8 ± 4.7 vs 20.6 ± 7.0, 24–48 h 25.9 ± 3.3 vs 27.4 ± 4.4. The esketamine arm's PCIA also held esketamine. Postoperative adverse events cover the first 48 h. Enrollment dates are the screening period stated in Results (Methods: October 2023 to June 2024); last follow-up July 28, 2024."
  },
  {
    "trial": "T126",
    "source": "preprint",
    "arms": {
      "Group R (ropivacaine ESP block)": {"randomized": "47", "analysed": "47"},
      "Group K1 (low-dose esketamine)": {"randomized": "45", "analysed": "45"},
      "Group K2 (high-dose esketamine)": {"randomized": "47", "analysed": "47"}
    },
    "depression": [
      {"measure": "HADS-D", "day": -1, "form": "mean_sd", "location": "Table 1, Preoperative HADS-D score",
       "values": {"Group R (ropivacaine ESP block)": {"mean": "4.6", "sd": "1.6", "n": "47"}, "Group K1 (low-dose esketamine)": {"mean": "4.3", "sd": "1.5", "n": "45"}, "Group K2 (high-dose esketamine)": {"mean": "4.8", "sd": "1.4", "n": "47"}}},
      {"measure": "HADS-D", "day": 0.5, "form": "mean_sd", "location": "Table 3, Postoperative HADS-D score, 12 h",
       "values": {"Group R (ropivacaine ESP block)": {"mean": "4.1", "sd": "1.4", "n": "47"}, "Group K1 (low-dose esketamine)": {"mean": "3.9", "sd": "1.3", "n": "45"}, "Group K2 (high-dose esketamine)": {"mean": "4.4", "sd": "1.5", "n": "47"}}},
      {"measure": "HADS-D", "day": 1, "form": "mean_sd", "location": "Table 3, Postoperative HADS-D score, 24 h",
       "values": {"Group R (ropivacaine ESP block)": {"mean": "3.3", "sd": "1.2", "n": "47"}, "Group K1 (low-dose esketamine)": {"mean": "2.9", "sd": "1.2", "n": "45"}, "Group K2 (high-dose esketamine)": {"mean": "3.3", "sd": "1.3", "n": "47"}}},
      {"measure": "HADS-D", "day": 2, "form": "mean_sd", "location": "Table 3, Postoperative HADS-D score, 48 h",
       "values": {"Group R (ropivacaine ESP block)": {"mean": "2.9", "sd": "1.8", "n": "47"}, "Group K1 (low-dose esketamine)": {"mean": "2.9", "sd": "1.4", "n": "45"}, "Group K2 (high-dose esketamine)": {"mean": "3.1", "sd": "1.5", "n": "47"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 3, 12 h",
       "values": {"Group R (ropivacaine ESP block)": {"dizziness": "5", "nightmare": "8"}, "Group K1 (low-dose esketamine)": {"dizziness": "5", "nightmare": "8"}, "Group K2 (high-dose esketamine)": {"dizziness": "3", "nightmare": "14"}}},
      {"window": "postoperative", "location": "Table 3, 24 h",
       "values": {"Group R (ropivacaine ESP block)": {"dizziness": "4", "nightmare": "4"}, "Group K1 (low-dose esketamine)": {"dizziness": "5", "nightmare": "5"}, "Group K2 (high-dose esketamine)": {"dizziness": "2", "nightmare": "4"}}},
      {"window": "postoperative", "location": "Table 3, 48 h",
       "values": {"Group R (ropivacaine ESP block)": {"dizziness": "9", "nightmare": "2"}, "Group K1 (low-dose esketamine)": {"dizziness": "10", "nightmare": "4"}, "Group K2 (high-dose esketamine)": {"dizziness": "6", "nightmare": "1"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2020-12-07", "end": "2021-04"},
    "registration": {"number": "ChiCTR2000040659", "date": "2020-12-07"},
    "note": "Esketamine was given in the ESP block mixed with ropivacaine, not intravenously. Randomized numbers are the abstract's ('139 patients were randomized to group R (n = 47), K1 (n = 45) and K2 (n = 47)'); Results say 150 recruited, 10 excluded, 'One patient withdrew from group K1. Thus, 139 patients randomized', so if the withdrawal came after allocation, K1 randomized would be 46. HADS-D at 12 h is entered as day 0.5. VAS at rest and while coughing (12, 24, 48 h) is only in Fig. 3 (mean ± SD, no printed values), not entered. Not entered: duration of ESP-block analgesia (time to first PCIA use, primary), R 784.2 ± 130.9, K1 845.0 ± 134.4, K2 894.5 ± 129.7 min, not a day-1 or day-2 score; remedial analgesia within 48 h, 31 (66) vs 21 (46.7) vs 9 (19.1). Adverse events are counts at 12, 24 and 48 h (Table 3), entered as three postoperative entries told apart by location; do not add them, since a patient may appear at several times. 'Dreamy' is entered as nightmare. Enrollment dates are from Results ('from December 7, 2020 to April 2021')."
  }
]